Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORION-1 study of AVZO-023 alone and in combination in advanced HR-positive/HER2-negative breast cancer
2026-525948-15-00Phase 2Authorised
- Sponsor
- Avenzo Therapeutics
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of AVZO-023 in breast cancer (4 arms), sponsored by Avenzo Therapeutics. Primary endpoints: Dose-limiting toxicities, Safety events and 3 more. Planned start Oct 2026; status: authorised.
02
Drugs
AVZO-023
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2026-525948-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525948-15-00.